Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT02819726

Public ClinicalTrials.gov record NCT02819726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis (RA)

Study identification

NCT ID
NCT02819726
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Archigen Biotech Limited
Industry
Enrollment
294 participants

Conditions and interventions

Interventions

  • MabThera Biological
  • Rituxan Biological
  • SAIT101 Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 10, 2016
Primary completion
Apr 29, 2018
Completion
Nov 6, 2018
Last update posted
Feb 16, 2020

2016 – 2018

United States locations

U.S. sites
15
U.S. states
8
U.S. cities
13
Facility City State ZIP Site status
Research Site Anniston Alabama 36207
Research Site El Cajon California 92020
Research Site La Mesa California 91942
Research Site Lakewood California 90712
Research Site-1 Los Angeles California 90017
Research Site-2 Los Angeles California 90017
Research Site San Leandro California 94578
Research Site Orlando Florida 32804
Research Site Tampa Florida 33612
Research Site Tampa Florida 33613
Research Site Boise Idaho 83642
Research Site Kansas City Kansas 66160
Research Site Lansing Michigan 48917
Research Site Waco Texas 76710
Research Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02819726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2020 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02819726 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →